Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients.
Szmania S et al. J Immunother. 2014 Nov 20. [Epub ahead of print].

Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation.
Binsfeld M et al. PLoS One. 2014 Nov 21;9(11):e113764. doi: 10.1371/journal.pone.0113764. eCollection 2014.

Exploration for the multi-effect of cardamom in’s resistance to multiple myeloma.
Zhihua Z et al. Pak J Pharm Sci. 2014 Nov;27(6 Suppl):2001-6.

Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.
Frassanito MA et al. Eur J Haematol. 2014 Nov 20. doi: 10.1111/ejh.12481. [Epub ahead of print].

Myeloid-derived suppressor cells: Their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.
Younos IH et al. Leuk Lymphoma. 2014 Nov 19:1-31. [Epub ahead of print].

Role of Decorin in Multiple Myeloma (MM) Bone Marrow Microenvironment.
Nemani N et al. J Bone Miner Res. 2014 Nov 18. doi: 10.1002/jbmr.2371. [Epub ahead of print].

Shed Syndecan-1 Translocates to the Nucleus of Cells Delivering Growth Factors and Inhibiting Histone Acetylation: A Novel Mechanism of Tumor-Host Crosstalk.
Stewart MD et al. J Biol Chem. 2014 Nov 17. pii: jbc.M114.608455. [Epub ahead of print].

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple MyelomaCells to Doxorubicin.
Alagpulinsa DA et al. Front Oncol. 2014 Oct 30;4:289. doi: 10.3389/fonc.2014.00289. eCollection 2014.

Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myelomapatients refractory to lenalidomide and bortezomib.
Nijhof IS et al. Clin Cancer Res. 2014 Nov 14. pii: clincanres.1813.2014. [Epub ahead of print].

RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Zhu YX et al. Blood. 2014 Nov 13. pii: blood-2014-05-577130. [Epub ahead of print].

Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Li A et al. J Mol Model. 2014 Nov;20(11):2515. doi: 10.1007/s00894-014-2515-y. Epub 2014 Nov 14.

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.
Paíno T et al. Leukemia. 2014 Nov 12. doi: 10.1038/leu.2014.321. [Epub ahead of print].

Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
Deshaies RJ et al. BMC Biol. 2014 Nov 11;12(1):94. doi: 10.1186/s12915-014-0094-0.

GP130 activation induces myeloma and collaborates with MYC.
Dechow T et al. J Clin Invest. 2014 Nov 10. pii: 69094. doi: 10.1172/JCI69094. [Epub ahead of print].

Clinicopathological significance and potential drug target of p15(INK4B) in multiple myeloma.
Li J et al. Drug Des Devel Ther. 2014 Oct 31;8:2129-36. doi: 10.2147/DDDT.S71088. eCollection 2014.

Mitochondrial genome of a multiple myeloma bone cancer disease model rat strain (Muridae; Rattus).
Huang C et al. Mitochondrial DNA. 2014 Nov 7:1-2. [Epub ahead of print].

Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients.
Bolkun L et al. Hematol Oncol. 2014 Nov 5. doi: 10.1002/hon.2182. [Epub ahead of print].

MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression.
Cho SF et al. BMC Cancer. 2014 Nov 4;14:809. doi: 10.1186/1471-2407-14-809.

Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo.
Zhang Q et al. Oncol Rep. 2015 Jan;33(1):448-56. doi: 10.3892/or.2014.3591. Epub 2014 Nov 5.

Differential impact of bortezomib on HL-60 and K562 cells.
Kliková K et al. Gen Physiol Biophys. 2014 Nov 4. [Epub ahead of print].

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
Varga G et al. Br J Haematol. 2014 Nov 3. doi: 10.1111/bjh.13197. [Epub ahead of print].

Interleukin-6 gene-174 G/C promoter polymorphism and its association with clinical profile of patients withmultiple myeloma.
Chakraborty B et al. Asia Pac J Clin Oncol. 2014 Oct 31. doi: 10.1111/ajco.12290. [Epub ahead of print].

Appraising myc involvement in high risk myeloma.
Kastritis E et al. Leuk Lymphoma. 2014 Nov 5:1-2. [Epub ahead of print].

Low-energy laser irradiation promotes cellular damage in glucocorticoid-resistant multiple myeloma cells.
Allegra A et al. Leuk Lymphoma. 2014 Nov 3:1-3. [Epub ahead of print].